Literature DB >> 9301995

Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes.

S Sriskandan1, A McKee, L Hall, J Cohen.   

Abstract

We have tested the ability of Streptococcus pyogenes to produce streptococcal pyrogenic exotoxin A (SPEA) and superantigenic activity in the presence of sub-inhibitory concentrations of ampicillin and clindamycin. After 6 h of culture, SPEA production by S. pyogenes was higher in broths containing ampicillin (715.7 +/- 296.4 pg/10(6) cfu) than in broths containing clindamycin (167.1 +/- 31.9 pg/10(6) cfu), a difference that was not significant (P = 0.25). Promitogenic activity of bacterial supernatants was also greater in ampicillin-treated cultures (467.5 +/- 17.2 ccpm/10(6) cfu) than in clindamycin-treated cultures (169.2 +/- 8.9 ccpm/10(6) cfu), a difference that was highly significant (P = 0.0001). The data support the use of clindamycin in the treatment of streptococcal toxic shock-like syndrome, in order to inhibit superantigen synthesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301995     DOI: 10.1093/jac/40.2.275

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  Growth-phase-dependent expression of virulence factors in an M1T1 clinical isolate of Streptococcus pyogenes.

Authors:  M Unnikrishnan; J Cohen; S Sriskandan
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

2.  Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes.

Authors:  Jun Sawai; Tadao Hasegawa; Takuya Kamimura; Akira Okamoto; Daisuke Ohmori; Nobuyuki Nosaka; Keiko Yamada; Keizo Torii; Michio Ohta
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

3.  Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis.

Authors:  Megumi Tanaka; Tadao Hasegawa; Akira Okamoto; Keizo Torii; Michio Ohta
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Analysis of the transcriptome of group A Streptococcus in mouse soft tissue infection.

Authors:  Morag R Graham; Kimmo Virtaneva; Stephen F Porcella; Donald J Gardner; R Daniel Long; Diane M Welty; William T Barry; Claire A Johnson; Larye D Parkins; Fred A Wright; James M Musser
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

Review 5.  Inflammatory properties of antibiotic-treated bacteria.

Authors:  Andrea J Wolf; George Y Liu; David M Underhill
Journal:  J Leukoc Biol       Date:  2016-08-30       Impact factor: 4.962

6.  Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin.

Authors:  Oana Dumitrescu; Sandrine Boisset; Cedric Badiou; Michele Bes; Yvonne Benito; Marie-Elisabeth Reverdy; François Vandenesch; Jerome Etienne; Gerard Lina
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

Review 7.  Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.

Authors:  Roland Nau; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

8.  Predictors of Monomicrobial Necrotizing Soft Tissue Infections.

Authors:  Rhett N Willis; Christopher A Guidry; Christopher B Horn; Daniel Gilsdorf; Stephen W Davies; Zachary C Dietch; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2015-06-25       Impact factor: 2.150

Review 9.  Staphylococcal skin infections in children: rational drug therapy recommendations.

Authors:  Shamez Ladhani; Mehdi Garbash
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

10.  Genetic commonality of macrolide-resistant group A beta hemolytic streptococcus pharyngeal strains.

Authors:  Angela L Myers; Mary Anne Jackson; Rangaraj Selvarangan; Richard V Goering; Christopher Harrison
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-12-01       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.